Dengue vaccine to be tested in India

November 19, 2012

French health care giant Sanofi Pasteur will soon test a vaccine against dengue fever in India amid concerns about the increasingly global spread of the disease, reports said Monday.

The vaccine will be tried on about 120 adults followed by trials on children before it can be made available internationally as soon as 2015, the Times of India newspaper said.

"Sites for the vaccine's final trials will stretch from Thailand to India as this vaccine has to work on populations across countries. We will test it in India soon," Sanofi's CEO Christopher Viehbacher was quoted as saying.

Dengue causes a flu-like illness for most victims but one of its strains can cause life-threatening internal bleeding.

There is no licensed vaccine to protect against dengue. Efforts to develop one have been complicated by the fact that there are four different strains, all of which may circulate in an outbreak zone.

Dengue also seems to be exclusive to humans, which means it is impossible to test vaccines on first.

Jean Lang, head of the vaccine's research and development programme, said Sanofi had been asked to conduct "phase two safety trials" in India by the national drug controller.

"It will help us get a licence to market the in India faster if it has been tested on the Indian population and is found safe and effective," Lang told the paper.

According to the UN's , between 50 and 100 million dengue infections occur each year in more than 100 countries. In 1970 the disease was endemic in just nine countries.

India, with a teeming population of 1.2 billion, has become a major focal point for the mosquito-borne viral infection.

Between 2007 and this month, the country has had 32,263 dengue cases with 188 deaths, according to the National Control Programme. Experts say the real numbers are much higher.

Explore further: Concerns over cost of dengue vaccine lessened with new study

Related Stories

Concerns over cost of dengue vaccine lessened with new study

June 28, 2012

Research funded by the Dengue Vaccine Initiative (DVI) involving an economic analysis of producing a tetravalent dengue vaccine shows that the cost could be as low as $0.20 per dose with an annual production level of 60 million ...

Progress reported with candidate dengue vaccine

July 25, 2012

Trials in Thailand with a candidate vaccine for dengue, a potentially fatal mosquito-borne disease, have shown it to protect against three of the four virus strains, its French maker said Wednesday.

Scientists make dengue vaccine breakthrough

September 10, 2012

Dengue is one of the most widespread mosquito-borne viral diseases in the world, with WHO estimating that around half of the world's population are currently at risk. While infection usually causes flu-like symptoms, it can ...

Recommended for you

Monkeys in Asia harbor virus from humans, other species

November 19, 2015

When it comes to spreading viruses, bats are thought to be among the worst. Now a new study of nearly 900 nonhuman primates in Bangladesh and Cambodia shows that macaques harbor more diverse astroviruses, which can cause ...

One-step test for hepatitis C virus infection developed

November 14, 2015

UC Irvine Health researchers have developed a cost-effective one-step test that screens, detects and confirms hepatitis C virus (HCV) infections. Dr. Ke-Qin Hu, director of hepatology services, will present findings at the ...

Computer model reveals deadly route of Ebola outbreak

November 10, 2015

Using a novel statistical model, a research team led by Columbia University's Mailman School of Public Health mapped the spread of the 2014-2015 Ebola outbreak in Sierra Leone, providing the most detailed picture to date ...


Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.